Olanzapine with ondansetron for the prevention of cisplatin-based chemotherapy-Induced Nausea and Vomiting in lung cancer
Background Olanzapine is an atypical antipsychotic that has shown efficacy for the treatment of nausea,anxiety and insomnia in patients.This prospective study was conducted to evaluate the efficacy of olanzapine combined with 5-HT3 receptor antagonists and dexamethasone for prevention of CINV in lung patients receiving cisplatin-based (25mg/m2 d1-3) highly emetogenic chemotherapy.Methods Olanzapine (5 mg) was administered a day prior to cisplatin administration and continued on days 1-5.We evaluated complete response rate (CR) and rates of no nausea and no vomiting in three periods.In addition,SAS,SDS and FLIE questionnaire were assessed the status of patients and quality of life.Results CR for acute,delayed,and over all phases were 82.5%,75.0%,and 70.0%.The rate of no nausea in the acute phase was 70.0% and 62.5% in delayed phase.The rate of no vomiting in the acute phase was 85.0%,and 77.5% in delayed phase.The rate of no nausea and no vomiting in the overall phase were 57.5% and 75.0%.The median SAS score and SDS were 37.9 and 41.6 in pre-chemotherapy.Up to day 6 after chemotherapy treatment,the median SAS score and SDS were 36.9 and 42.0.The median FLIE score was 111.7.The main side effects were grade 1 somnolence (35.0%) and mild constipation (52.5 %).Conclusions 5mg olanzapine may be used as a potential,safe,and cost beneficial alternative to prevent nausea and vomiting in HEC,particular for multiday chemotherapy regimen.
Olanzapine Nausea Vomiting Prevention Chemotherapy-induced
Wenxian Wang Guangyuan Lou Yiping Zhang
Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang province, China Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang province, China;Key Laborat
国内会议
第八届同德国际学术周第三届中西结合肿瘤论坛、2017年浙江省抗癌协会康复与姑息专业委员会年会
杭州
英文
86-97
2017-10-01（万方平台首次上网日期，不代表论文的发表时间）